Clinical Trials Logo

Pancreatitis, Acute clinical trials

View clinical trials related to Pancreatitis, Acute.

Filter by:

NCT ID: NCT02947932 Not yet recruiting - Clinical trials for Gastrointestinal Disease

Oral Resveratrol to Prevent Post-ERCP Pancreatitis

Start date: December 2016
Phase: Phase 4
Study type: Interventional

Acute pancreatitis is the most common and feared complication of ERCP, occurring after 1% to 30% of procedures. Since 2012, a multicenter RCT was published in NEJM, indomethacin use in high risk patients was considered a "standard" method to prevent PEP. However, the risk factors of PEP is not fully clear. Additionally, the complication of NSAID use lead to some serious physical problem bleeding. Therefore, the exclusive criteria for limiting the NSAID use is including allergy, gastrointestinal haemorrhage ,presence of coagulopathy or received anticoagulation therapy. Previous study showed that another natural compound, resveratrol, owns similar biological effect with NSAID. Firstly, it could inhibit the inflammatory response on in vivo model through inhibition of COX and IL-6 etc. Secondly, it could not influence the level of platelet and coagulation, which means safer than NSAID. Thirdly, numerous studies showed that resveratrol could effectively the progression of severe acute pancreatitis. According to data, we design the project. The purpose of this study is to determine whether oral resveratrol pre-ERCP is effective on control of Post-ERCP pancreatitis.

NCT ID: NCT00490386 Completed - Pancreatitis, Acute Clinical Trials

Helicobacter Pylori and Acute Alcohol Induced Pancreatitis

Start date: June 2006
Phase: N/A
Study type: Observational

This study is performed to measure wether Helicobacter Pylori has an effect on the incidence and course of acute alcohol induced pancreatitis